316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

Andrew Joseph, STAT's Europe correspondent, dives into the 40-year journey of developing malaria vaccines, shedding light on the immense collaborative efforts in sub-Saharan Africa. He also examines Sarepta Therapeutics’ controversial censorship of a patient video, raising questions about transparency in gene therapy. The conversation reveals the ethical dilemmas faced by patients and the impact of corporate influence on advocacy. Additionally, Joseph discusses Mount Sinai's attempts to suppress discussions on their contentious brain research, illustrating challenges in accountability within the biotech industry.